What Hyaluronidase Cannot Do: Non-HA Filler Complications

Hyaluronidase and non-HA filler are a mismatch at the level of chemistry, and no amount of dose escalation changes that. The enzyme cleaves hyaluronan. Calcium hydroxylapatite is a mineral microsphere suspended in a carboxymethylcellulose carrier. Poly-L-lactic acid is a polyester microparticle. Neither has a glycosaminoglycan backbone, neither is a substrate, and neither will degrade no matter how many units you put around it.

Michelle Langston states the limit plainly and then, in the same breath, tells injectors to use the enzyme anyway. "It does not reverse non-HA fillers. So we need to understand that… However, you should still move into your hyaluronidase to decrease the compression around those vessels."

That looks contradictory until you separate two different goals. Dissolving the occlusive material is one goal. Restoring perfusion to ischemic tissue is another. For a hyaluronic acid event they are the same intervention. For a biostimulator event they are not, and the consequence is not primarily a change of drug — it is a change of timeline.

Why there is no substrate

Hyaluronidase depolymerises hyaluronan by cleaving the glycosidic linkage between its two component sugars. Enzymes are substrate-specific; the active site recognises a particular molecular geometry and does nothing to molecules that do not present it.

Calcium hydroxylapatite microspheres are an inorganic calcium phosphate ceramic. Their gel carrier is carboxymethylcellulose, a cellulose derivative. Poly-L-lactic acid microparticles are a synthetic polyester that hydrolyses slowly over months and then stimulates a collagen response. Polymethylmethacrylate is an acrylic polymer. Autologous fat is adipose tissue. None of these is a glycosaminoglycan.

So when a CaHA or PLLA product embolises, you have no agent that removes it. That is the honest starting point, and it should change how you think about the event before it happens rather than during it.

Why you still inject

Langston's rationale is compressive. The goal is to reduce the total load on the compromised vessel and its surroundings so that whatever flow can be restored, is.

Two things contribute to that load. One is the occlusive material itself, which you cannot touch. The other is everything around the vessel: the native hyaluronan in the extracellular matrix, the interstitial fluid it binds, and the oedema generated by the ischemic and inflammatory response. Hyaluronidase degrades native matrix hyaluronan, reduces interstitial viscosity and increases tissue permeability. In a territory that is swelling, that is not nothing — it reduces extrinsic pressure on vessels and improves the movement of fluid and of any other agent you give through the tissue.

There is a second consideration that argues for the same action from the opposite direction. Patients are layered. A face that received Radiesse in the midface eight weeks ago may also carry hyaluronic acid product in the same territory from a previous session, or from the same session. Langston's colleagues teach layering as routine practice, and our overview of biostimulators versus fillers covers why the two classes are so often combined. If you are certain the occlusive agent is CaHA, you may still be wrong about what else is in the tissue — and if you are wrong in the other direction, withholding the enzyme costs you the one definitive treatment available.

The evidence position. Langston refers to "literature" supporting hyaluronidase use in non-HA events without naming a source. Empire has not been able to identify a specific citation behind that reference, so we present the practice as her taught protocol rather than as a sourced recommendation. To be clear about what the evidence base looks like: the rationale is mechanistic and the published material consists of expert consensus and case reports rather than controlled trials. There is no protocol establishing efficacy of hyaluronidase for non-HA vascular occlusion, and you should not expect the enzyme to behave as definitive therapy the way it does for an HA event. It is a supportive measure taken while you arrange something better.

The escalation threshold moves earlier — this is the whole point

This is the operational consequence that matters, and it is the thing to change on Monday morning.

For a hyaluronic acid vascular event, the enzyme is definitive treatment. That is what justifies the in-office cycle: flood the territory, reassess at 15 to 20 minutes, repeat, and keep going until capillary refill and colour return. You are not delaying transfer by running that cycle. You are administering the treatment the hospital would give, and running it in your own chair is appropriate and often sufficient.

For a CaHA or PLLA event, you have no definitive in-office treatment. The reassess-and-repeat cycle is not therapy that might resolve the problem. It is a holding action while you arrange escalation. Which means the reason for waiting — let me see whether this responds — has been removed.

Langston is explicit about the change: "If you have a biostimulator complication, if you're using calcium hydroxylapatite, Radiesse, or Sculptra, immediately you're going to go into your emergency protocol. You're going to start flooding. Nothing is going to change. But instead of waiting for pulling emergency, we are going to do that right when this happens."

Read that carefully. Nothing is going to change refers to what you do with your hands — same protocol, same flooding, same territory. What changes is when you call. The call goes out at the point of suspicion rather than at the end of a failed treatment cycle.

Three practical consequences follow.

Time to transfer is your only real lever. Everything else in your protocol is supportive. The variable you control is how fast the patient reaches a facility with more capability than you have.

The agent has to be in the handoff message. An emergency physician told "filler occlusion" will assume hyaluronic acid, because that is what most of them are. Say the product name and the class, and say that hyaluronidase does not reverse it. This materially changes what the receiving team considers.

Know the risk before you inject it. Biostimulator days are different-risk days. If your protocol is to transfer earlier for these agents, then the staffing, the supply and the phone numbers should be reviewed before the biostimulator patient is in the chair, not discovered mid-event. Empire's Facial Contouring Injectables workshop covers the Sculptra and Radiesse product classes alongside their handling and placement.

The other agents the enzyme does not touch

The same logic extends beyond the biostimulators most practices stock.

Polymethylmethacrylate is a permanent acrylic microsphere product. Nothing dissolves it, and complications involving it are surgical problems.

Autologous fat is living tissue. Fat embolism after facial grafting is a recognised and serious event, and the enzyme has no role in removing the embolised material.

Unregulated and illegal injectables — silicone, unidentified products injected abroad or by unlicensed injectors — present the additional problem that you may not know what the material is. Patients frequently do not know either. A patient with an unclear injection history and a vascular presentation should be escalated early on the same reasoning: you cannot treat what you cannot identify.

The layered patient is the trap that runs in the opposite direction. If a territory contains both HA and non-HA product, flooding may produce a partial response. Partial response in this setting is genuinely dangerous, because it reads as progress. You may have dissolved the hyaluronic acid contribution to the compression while leaving the actual occlusive embolus untouched. Judge by perfusion — capillary refill, colour, temperature — against the patient's baseline, not by whether things look somewhat better than they did ten minutes ago. Langston's rule for HA events applies with more force here: treat until the patient is clinically back where they started, and escalate if you are not getting there.

What this looks like in practice

The moment you suspect a vascular event in a territory where you placed a biostimulator:

1. Stop injecting. Put the syringe down.
2. Assess — capillary refill, colour, temperature, pain, and vision.
3. Activate the emergency protocol immediately, including the call for transfer. Do not wait for a treatment cycle to fail.
4. Begin flooding the affected territory with hyaluronidase to reduce compressive load, and continue while you wait.
5. Mark, outline and timestamp the affected border, and photograph serially.
6. Keep the patient with you. Do not send them to the emergency department alone.
7. Name the agent explicitly to the receiving clinician.

The sequence is short because the decision has been made in advance. That is the design. Langston's recurring point — that the preparation happens when there is no emergency — has a particular application here: the threshold for a biostimulator event should be written into your protocol document before you ever stock the product.

These protocols reflect Michelle Langston's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

For background on how these products behave and why they are chosen, see our overviews of Sculptra injections and facial collagen stimulation. For the mechanism of the enzyme itself and why territory flooding works at all, see the companion piece on what hyaluronidase actually does. The anatomical knowledge that lets you identify the perfusion territory at risk is covered in Anatomical Based Aesthetics Training.

Related guides in this cluster

Part of Vascular Occlusion: Recognition and Response.

Clinical GuideThe Expected Filler Injection Response — Building the Baseline That Lets You Recognize IschemiaThe expected filler injection response — erythema, edema, ecchymosis — and how a trained normal baseline makes early ischemia recogniza Clinical GuideThe Golden Triangle — Why the Filler Deposit Site Isn't Where You Put the Needle InThe filler deposit site sits at the needle tip, not the entry point — about half an inch away, further with a cannula. Why that gap dec Clinical GuideImmediate, Early and Late — The Three Windows of Vascular Occlusion OnsetVascular occlusion onset is not one moment. Organize the picture into immediate, early and late windows — detection runs days past the